drugset
drugset / Trial / NCT00374231

Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients

NCT00374231 ↗

Phase 4 Completed 40 enrolled University of Cincinnati Astellas Pharma Inc · collab
NaSingle-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of early corticosteroid discontinuation in liver transplant recipients more than 90 days post transplant, utilizing a combination of two drugs (tacrolimus and mycophenolate mofetil) for maintenance immunosuppressant therapy.

Timeline

Start
2002-10
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisone Other / unclassified — Oral
Background Mycophenolate Mofetil Small molecule — Oral
Background Tacrolimus Small molecule — Oral

Indications

No indication recorded.